RxDoctor Payments DataLook up a doctor →

Michael Manogue, MD

Clinical Cardiac Electrophysiology · Asheville, NCNPI 1417183054

Payments from drug & device makers

$236,711in general payments, 2019–2025

Across 566 payments — averaging $418.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$156K
  • Medtronic$68K
  • Abbott$7K
  • Biosense Webster, Inc.$4K
  • Atricure, Inc.$486
  • Biotronik Inc.$382
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$25,68811%
  • Speaking & faculty fees$168,62773%
  • Travel & lodging$15,6817%
  • Food & beverage$19,9479%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$236,711 in reported general payments places this provider in the 85th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

See all clinical cardiac electrophysiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$345,192
Medicare patients
710
Services billed
4,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$260,945
XareltoRivaroxaban114$135,741
EntrestoSacubitril/Valsartan42$35,548
MultaqDronedarone Hcl15$30,415
Dofetilide154$21,977
JardianceEmpagliflozin14$10,183
Metoprolol Succinate157$3,497
Flecainide Acetate38$1,404
Clonidine12$927
Amiodarone Hcl84$907
Mupirocin118$856
Atorvastatin Calcium41$655
Spironolactone55$503
SotalolSotalol Hcl32$448
Lisinopril41$445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$168$260,945242 claims
Johnson & JohnsonXarelto$115$135,741114 claims
NovartisEntresto$27$35,54842 claims
Boehringer IngelheimJardiance$85$10,18314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

Other clinical cardiac electrophysiology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →